Scuteri Damiana, Rombolà Laura, Natoli Silvia, Pisani Antonio, Bonsi Paola, Watanabe Chizuko, Bagetta Giacinto, Tonin Paolo, Corasaniti Maria Tiziana
Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Life (Basel). 2021 Jan 12;11(1):41. doi: 10.3390/life11010041.
DYT1 dystonia is the most common form of early-onset inherited dystonia, which is caused by mutation of torsin A (TA) belonging to the "ATPases associated with a variety of cellular activities" (AAA + ATPase). Dystonia is often accompanied by pain, and neuropathic pain can be associated to peripherally induced movement disorder and dystonia. However, no evidence exists on the effect of gabapentin in mice subjected to neuropathic pain model overexpressing human normal or mutated TA.
Mice subjected to L5 spinal nerve ligation (SNL) develop mechanical allodynia and upregulation of the α2δ-1 L-type calcium channel subunit, forming a validated experimental model of neuropathic pain. Under these experimental conditions, TA is expressed in dorsal horn neurons and astrocytes and colocalizes with α2δ-1. Similar to this subunit, TA is overexpressed in dorsal horn 7 days after SNL. This model has been used to investigate (1) basal mechanical sensitivity; (2) neuropathic pain phases; and (3) the effect of gabapentin, an α2δ-1 ligand used against neuropathic pain, in non-transgenic (NT) C57BL/6 mice and in mice overexpressing human wild-type (hWT) or mutant (hMT) TA.
In comparison to non-transgenic mice, the threshold for mechanical sensitivity in hWT or hMT does not differ (Kruskal-Wallis test = 1.478; = 0.4777, although, in the latter animals, neuropathic pain recovery phase is delayed. Interestingly, gabapentin (100 mg/Kg) reduces allodynia at its peak (occurring between post-operative day 7 and day 10) but not in the phase of recovery.
These data lend support to the investigation on the role of TA in the molecular machinery engaged during neuropathic pain.
DYT1肌张力障碍是早发性遗传性肌张力障碍最常见的形式,由属于“与多种细胞活动相关的ATP酶”(AAA + ATP酶)的扭转蛋白A(TA)突变引起。肌张力障碍常伴有疼痛,神经性疼痛可能与外周诱导的运动障碍和肌张力障碍有关。然而,尚无证据表明加巴喷丁对过表达人正常或突变TA的神经性疼痛模型小鼠的影响。
接受L5脊神经结扎(SNL)的小鼠会出现机械性异常疼痛以及α2δ-1 L型钙通道亚基上调,形成一个经过验证的神经性疼痛实验模型。在这些实验条件下,TA在背角神经元和星形胶质细胞中表达,并与α2δ-1共定位。与该亚基类似,SNL后7天TA在背角中过表达。该模型已用于研究:(1)基础机械敏感性;(2)神经性疼痛阶段;(3)加巴喷丁(一种用于治疗神经性疼痛的α2δ-1配体)对非转基因(NT)C57BL / 6小鼠以及过表达人野生型(hWT)或突变型(hMT)TA的小鼠的影响。
与非转基因小鼠相比,hWT或hMT小鼠的机械敏感性阈值没有差异(Kruskal-Wallis检验= 1.478;P = 0.4777),尽管在后者动物中,神经性疼痛恢复阶段有所延迟。有趣的是,加巴喷丁(100 mg / Kg)在其峰值(术后第7天至第10天之间出现)时可减轻异常性疼痛,但在恢复阶段则无效。
这些数据支持对TA在神经性疼痛过程中参与的分子机制中的作用进行研究。